Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral iron chelators--development and application.

Ding Y Liu1, Zu D Liu, Robert C Hider

  • 1Department of Pharmacy, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NN, UK.

Best Practice & Research. Clinical Haematology
|October 29, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiotracers for in situ infection imaging: Experimental considerations for in vitro microbial uptake of gallium-68-labeled siderophores.

Diagnostic microbiology and infectious disease·2024
Same author

[<sup>68</sup>Ga]Ga-Schizokinen, a Potential Radiotracer for Selective Bacterial Infection Imaging.

ACS infectious diseases·2024
Same author

The iron(III) coordinating properties of citrate and α-hydroxycarboxylate containing siderophores.

Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine·2024
Same author

The Colorimetric Detection of the Hydroxyl Radical.

International journal of molecular sciences·2023
Same author

Targeting integrin αvβ6 with gallium-68 tris (hydroxypyridinone) based PET probes.

Dalton transactions (Cambridge, England : 2003)·2022
Same author

PSMA-targeted NIR probes for image-guided detection of prostate cancer.

Colloids and surfaces. B, Biointerfaces·2022

New orally active iron chelators are needed for transfusion-dependent patients, as the current standard treatment has poor oral availability. Research focuses on tridentate and bidentate molecules for enhanced iron excretion.

Area of Science:

  • Pharmacology
  • Hematology
  • Medicinal Chemistry

Background:

  • Iron chelation therapy is crucial for managing iron overload in beta-thalassaemia major and other transfusion-dependent anemias.
  • Desferrioxamine, a long-standing treatment, exhibits poor oral bioavailability, necessitating alternative therapies.

Purpose of the Study:

  • To explore the development of non-toxic, orally active iron chelators with improved therapeutic profiles.
  • To identify ideal chelating agents with high iron affinity, controlled distribution, and low toxicity.

Main Methods:

  • Investigated physicochemical and biological properties of potential iron chelators.
  • Focused on tridentate and bidentate ligand structures, including triazoles and hydroxypyridinones.
  • Assessed oral absorption and iron excretion efficacy.

Related Experiment Videos

Main Results:

  • Tridentate triazoles show promise due to gastrointestinal absorption and effective iron excretion.
  • Bidentate hydroxypyridinones also demonstrate potential as orally active iron chelating agents.
  • Hexadentate ligands generally exhibit poor oral bioavailability.

Conclusions:

  • Orally active chelators, particularly tridentate triazoles and bidentate hydroxypyridinones, offer a promising alternative to desferrioxamine.
  • Further research into these agents could lead to improved treatment for iron overload disorders.